MRL20 is a selective PPARγ modulator (SPPARγM) which exhibits robust anti-diabetic activity with an improved therapeutic window in comparison to a PPARγ full agonist in a rodent efficacy model. References: Brust R, Lin H, Fuhrmann J, Asteian A, Kamenecka TM, Kojetin DJ. Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor. ACS Chem Biol. 2017 Apr 21;12(4):969-978. doi: 10.1021/acschembio.6b01015. Epub 2017 Feb 16. PubMed PMID: 28165718; PubMed Central PMCID: PMC5652320.

纯度：≥98%

CAS：393794-32-6